Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors | BioSpace

Published: Jul 10, 2024 By Tristan Manalac

Amgen office in FL_iStock, JHVEPhoto

Pictured: Amgen’s office in Tampa, Florida/iStock, JHVEPhoto

Amgen on Monday terminated the development of its investigational bispecific T-cell engager AMG 794, which it had been studying in a Phase I trial for several solid tumors including non-small cell lung cancer and epithelial ovarian cancer.

In an update to the clinicaltrials.gov website, the company noted that it “made the business decision to discontinue development of AMG 794” while maintaining that “the safety profile of AMG 794 remains unchanged.” It is not clear what exactly led to the termination of the AMG 794 program.

In line with the discontinuation of AMG 794, Amgen will also stop the Phase I study which was assessing the safety and tolerability of the bispecific T cell engager in several malignant solid tumor…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks